BRCA1/2 Germline Mutations and Their Clinical Importance in Turkish Breast Cancer Patients

REFERENCES

• Downs-Holmes C, Silverman P. Breast cancer: overview and updates. The Nurse Practitioner 2011;12:20–26.
   Google Scholar
• Key TJ, Verkasalo PK. Banks E epidemiology of breast cancer. Lancet Oncol 2001;2:133–140.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute, 2011.
   Google Scholar
• Ozmen V, Ozcinar B, Karanlik H. Breast cancer risk factors in Turkish women—a University Hospital based nested case control study. World J Surg Oncol 2009;8:7–37.
   Google Scholar
• Kim Y, Choi JY, Lee KM, Park SK, Ahn SH, Noh DY, Hong YC, Kang D, Yoo KY. Dose dependent protective effect of breast feeding against breast cancer among ever lactated women in Korea. Eur J Cancer Prev 2007;16:124–129.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Tuncer M. Significance of cancer in Turkey, the burden of disease and cancer control policies. Health Ministry Pub 2008;74:5–9.
   Google Scholar
• Egeli U, Cecener G, Tunca B, Tasdelen I. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives. Cancer Invest 2006;24: 484–491.
   PubMed Web of Science ®Google Scholar
• Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997;60:1013–1020.
   PubMed Web of Science ®Google Scholar
• Ferla R, Calò V. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007;6:93–98.
   Google Scholar
• Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505–514.
   PubMed Web of Science ®Google Scholar
• Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997;60:1059–1067.
   PubMed Web of Science ®Google Scholar
• Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198–200.
   PubMed Web of Science ®Google Scholar
• Robles-Diaz L, Goldfrank DJ, Kauff ND, Robson M, Offit K. Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 2004;3:259–264.
   PubMedGoogle Scholar
• Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, Lee MK, Goode EL, Rowell SE, King MC. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995;57:1284–1297.
   PubMed Web of Science ®Google Scholar
• Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185–187.
   PubMed Web of Science ®Google Scholar
• Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, Skolnick M, Shattuck-Eidens D, Jhanwar S, Goldgar D, Offit K. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126–128.
   PubMed Web of Science ®Google Scholar
• Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjörd JE. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996;13:117–119.
   PubMed Web of Science ®Google Scholar
• Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A, Ingvarsson S, Easton DF, Egilsson V, Barkardottir RB. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3663–3665.
   PubMed Web of Science ®Google Scholar
• Bergthorsson JT, Jonasdottir A, Johannesdottir G, Arason A, Egilsson V, Gayther S, Borg A, Hakanson S, Ingvarsson S, Barkardottir RB. Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. Hum Mutat 1998;1:195–197.
   Google Scholar
• Rafnar T, Benediktsdottir KR, Eldon BJ, Gestsson T, Saemundsson H, Olafsson K, Salvarsdottir A, Steingrimsson E, Thorlacius S. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur J Cancer 2004;40:2788–2793.
   PubMed Web of Science ®Google Scholar
• Møller P, Heimdal K, Apold J, Fredriksen A, Borg A, Hovig E, Hagen A, Hagen B, Pedersen JC, Maehle L; Norwegian Inherited Breast Cancer Group; Norwegian Inherited Ovarian Cancer Group. Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 2001;37:2428–2434.
   PubMed Web of Science ®Google Scholar
• Heimdal K, Maehle L, Apold J, Pedersen JC, Møller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur J Cancer 2003;39:2205–2213.
   PubMed Web of Science ®Google Scholar
• Rudkin TM, Hamel N, Galvez M, Hogervorst F, Gille JJ, Møller P, Apold J, Foulkes WD. The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. BMC Med Genet 2006;1:7–15.
   Google Scholar
• Reeves MD, Yawitch TM, van der Merwe NC, van den Berg HJ, Dreyer G, van Rensburg EJ. BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families. Int J Cancer 2004;110:677–682.
   PubMed Web of Science ®Google Scholar
• Vega A, Campos B, Bressac-De-Paillerets B, Bond PM, Janin N, Douglas FS, Domènech M, Baena M, Pericay C, Alonso C, Carracedo A, Baiget M, Diez O. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 2001;419:1–6.
   Google Scholar
• Grzybowska E, Siemińska M, Zientek H, Kalinowska E, Michalska J, Utracka-Hutka B, Rogozińska-Szczepka J, Kaźmierczak-Maciejewska M. Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population. Acta Biochim Pol 2002;49:351–356.
   PubMed Web of Science ®Google Scholar
• Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, Zidovska J, Novotny J, Petruzelka L, Szabo C, Matous B. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 2005;7:728–736.
   Google Scholar
• Cierniková S, Tomka M, Kovác M, Stevurková V, Zajac V. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma 2006;53:97–102.
   PubMed Web of Science ®Google Scholar
• Gronwald J, Elsakov P, Górski B, Lubiński J. High incidence of 4153delA BRCA1 gene mutations in Lithuanian breast and breast-ovarian cancer families. Breast Cancer Res Treat 2005;94: 111–113.
   PubMed Web of Science ®Google Scholar
• Hamel N, Feng BJ, Foretova L, Stoppa-Lyonnet D, Narod SA, Imyanitov E, Sinilnikova O, Tihomirova L, Lubinski J, Gronwald J, Gorski B, Hansen Tv, Nielsen FC, Thomassen M, Yannoukakos D, Konstantopoulou I, Zajac V, Ciernikova S, Couch FJ, Greenwood CM, Goldgar DE, Foulkes WD. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 2011;19:300–306.
   PubMed Web of Science ®Google Scholar
• Laitman Y, Simeonov M, Herskovitz L, Kushnir A, Shimon-Paluch S, Kaufman B, Zidan J, Friedman E. Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel. Breast Cancer Res Treat 2012;133:1153–1157.
   PubMed Web of Science ®Google Scholar
• Balci A, Huusko P, Pääkkönen K, Launonen V, Uner A, Ekmekçi A, Winqvist R. Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3424del4 found in male breast cancer. Eur J Cancer 1999;35:707–710.
   PubMed Web of Science ®Google Scholar
• Ozdag H, Tez M, Sayek I, Muslumanoglu M, Tarcan O, Içli F, Oztürk M, Ozçelik T. Germline BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients. Eur J Cancer 2000;36:2076–2082.
   PubMed Web of Science ®Google Scholar
• Yazici H, Bitisik O, Akisik E, Cabioglu N, Saip P, Muslumanoglu M, Glendon G, Bengisu E, Ozbilen S, Dincer M, Turkmen S, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. Br J Cancer 2000;83:737–742.
   PubMed Web of Science ®Google Scholar
• Manguoglu AE, Lüleci G, Ozçelik T, Colak T, Schayek H, Akaydin M, Friedman E. Germline mutations in the BRCA1and BRCA2 genes in Turkish breast/ovarian cancer patients. Hum Mutat 2003;21:444–445.
   PubMedGoogle Scholar
• Yazici H, Glendon G, Yazici H, Burnie SJ, Saip P, Buyru F, Bengisu E, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in nonfamilial cases. Hum Mutat 2002;20:28–34.
   PubMed Web of Science ®Google Scholar
• Aktas D, Gultekin M, Kabacam S, Alikasifoglu M, Turan AT, Tulunay G, Kose MF, Ortac F, Yüce K, Tunçbilek E, Ayhan A. Identification of point mutations and large rearrangements in the BRCA1 gene in 667 Turkish unselected ovarian cancer patients. Gynecol Oncol 2010;119:131–135.
   PubMed Web of Science ®Google Scholar
• Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006;43:295–305.
   PubMed Web of Science ®Google Scholar
• Desmet FO, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, Béroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucl Acids Res 2009;37:1–14.
   PubMedGoogle Scholar
• Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G. BRCAPRO validation. Sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002;20:2701–2712.
   PubMed Web of Science ®Google Scholar
• Chan PA, Duraisamy S, Miller PJ, Newell JA, McBride C, Bond JP, Raevaara T, Ollila S, Nyström M, Grimm AJ, Christodoulou J, Oetting WS, Greenblatt MS. Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum Mutat 2007;28:683–693.
   PubMed Web of Science ®Google Scholar
• Thusberg J, Vihinen M. Pathogenic or not? And if so, then how? Studying the effects of missense mutations using bioinformatics methods. Hum Mutat 2009;30:703–714.
   PubMed Web of Science ®Google Scholar
• Tunca B, Pedroni M, Cecener G, Egeli U, Borsi E, Zorluoglu A, Gregorio CD, Yilmazlar T, Yerci O, and Ponz de Leon M. Analysis of mismatch repair gene mutations in Turkish HNPCC patients. Familial Cancer 2010;9:365–376.
   PubMed Web of Science ®Google Scholar
• Osorio A, Barroso A, Martínez B, Cebrián A, San Román JM, Lobo F, Robledo M, Benítez J. Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 2000;82:1266–1270.
   PubMed Web of Science ®Google Scholar
• Goelen G, Teugels E, Bonduelle M, Neyns B, De Grève J. High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. J Med Genet 1999;36:304–308.
   PubMed Web of Science ®Google Scholar
• Stuppia L, Di Fulvio P, Aceto G, Pintor S, Veschi S, Gatta V, Colosimo A, Cianchetti E, Cama A, Mariani-Costantini R, Battista P, Palka G. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy. Hum Mutat 2003;22:178–179.
   PubMedGoogle Scholar
• Meindl A. German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002;97:472–480.
   PubMed Web of Science ®Google Scholar
• Verhoog LC, Van den Ouweland AM, Berns E, Van Veghel-Plandsoen MM, Van Staveren IL, Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, Halley DJ, Niermeijer MF, Klijn JG, Meijers-Heijboer H. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 2001; 16: 2082–2090.
   Google Scholar
• Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi OP, Muhonen T, Luce M, Frank TS, Nevanlinna H. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 1997;13:2309–2315.
   Google Scholar
• Ghaderi A, Talei A, Farjadian S, Mosalaei A, Doroudchi M, Kimura H. Germline BRCA1 mutations in Iranian women with breast cancer. Cancer Lett 2001;165:87–94.
   PubMed Web of Science ®Google Scholar
• Cecener G. Frame-Shift Mutations in BRCA1 and BRCA2 Genes in Turkish Families with Breast and/or Ovarian Cancer, New York: Nova Biomedical Books, 2010.
   Google Scholar
• Borg A, Haile RW, Malone KE, Capanu M, Diep A, Törngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, Mellemkjaer L, Bernstein L, Tellhed L, Xue S, Olson ER, Liang X, Dolle J, Børresen-Dale AL, Bernstein JL. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the Wecare study. Hum Mutat Brief 2010;31:1200–1240.
   PubMed Web of Science ®Google Scholar
• Güran S, Ozet A, Dede M, Gille JJ, Yenen MC. Hereditary breast cancer syndromes in a Turkish population. Results of molecular germline analysis. Cancer Genet Cytogen 2005;160:164–168.
   PubMed Web of Science ®Google Scholar
• Cartegni L, Wang J, Zhu Z. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003;31: 3568–3571.
   PubMed Web of Science ®Google Scholar
• Sironi M, Menozzi G, Riva L, Cagliani R, Comi GP, Bresolin N, Giorda R, Pozzoli U. Silencer elements as possible inhibitors of pseudoexon splicing. Nucleic Acids Res 2009;32:1783– 1791.
   Google Scholar
• Zhang C, Li WH, Krainer AR, Zhang MQ. RNA landscape of evolution for optimal exon and intron discrimination. Proc Natl Acad Sci USA 2008;105:5797–5802.
   PubMed Web of Science ®Google Scholar
• Quiles F, Fernández-Rodríguez J, Mosca R, Feliubadaló L, Tornero E, Brunet J, Blanco I, Capellá G, Pujana MÀ, Aloy P, Monteiro A, Lázaro C. Functional and structural analysis of C-terminal BRCA1 missense variants. PLoS One. 2013;17:1–6.
   Google Scholar
• Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN, Arun B. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer 2009;115:725–730.
   PubMed Web of Science ®Google Scholar
• Balman J, Diez O, Rubio IT, Cardoso F. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22:31–34.
   Google Scholar
• Vaz FH, Machado PM, Brandão RD, Laranjeira CT, Eugénio JS, Fernandes AH, André SP. Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients. J Histochem Cytochem 2007;55:1105–1113.
   PubMed Web of Science ®Google Scholar